Japan FY26 Drug Price Revision Cuts 15,800 Medicines
Japan’s FY26 National Health Insurance (NHI) drug price revision has taken effect, according to GlobalData analysis published on May 8, 2026. The policy reduces prices across approximately 15,800 medicines by an average of 4.02% and expands the G1 repricing framework. Consequently, it intensifies pricing pressure on off-patent drugs and biologics, while reshaping global pharmaceutical pricing expectations.
73% of Japanese Pharma Products Face Price Changes in April 2026
GlobalData reports that 73% of pharmaceutical products in Japan experienced a price change in April 2026. However, most of these adjustments resulted in reductions. In fact, 61% of medicines recorded direct price cuts, while only 12% saw price increases. Therefore, the overall market trend clearly points toward sustained downward pricing pressure across the sector.
Why Japan’s Biennial Pricing System Is Reshaping Global Pharma Economics
Japan continues to apply a structured biennial pricing system as a cost-containment strategy. Moreover, the FY26 revision combines market-based repricing with policy-driven interventions. As a result, the system not only controls domestic healthcare spending but also influences global pharmaceutical pricing behavior through predictable downward adjustments.
G1 Repricing Expansion Intensifies Pressure on Off-Patent Drugs
The expansion of the G1 repricing mechanism represents one of the most significant changes in FY26. Under the revised framework, eligibility now depends on competition exposure rather than substitution thresholds. Consequently, more off-patent medicines and biologics fall under repricing rules, which increases overall price reduction pressure across the market.
Biologics and Long-Listed Drugs Face Stronger Price Cuts
The updated system significantly impacts long-listed medicines and biologics with biosimilar competition. In fact, approximately 69% of off-patent small molecules and 95% of off-patent biologics experienced price reductions. Therefore, the revision highlights a clear shift toward stricter pricing control in high-value therapeutic segments.
Japan Maintains Innovation Protection Through PMP Program
Despite downward pricing pressure, Japan continues to protect innovative drugs through the Patent-Period Price Maintenance Program (PMP). This mechanism allows branded medicines to maintain listed prices during patent protection. However, the FY26 revision also introduces deferred adjustments, which now apply to drugs that previously avoided price reductions.
Deferred Price Cuts Hit Blockbuster Therapies Above 30%
Several widely used therapies now face significant deferred reductions under the revised framework. For example, certain drugs experienced cuts exceeding 30%, including high-profile treatments such as AstraZeneca’s Forxiga and Taiho Pharmaceutical’s Abraxane. Therefore, even protected products are no longer fully insulated from pricing corrections.
What Japan FY26 Drug Price Revision Means for Global Pharma Strategy
Although the average reduction rate is slightly lower than FY24, the FY26 revision expands the scope of products affected. As a result, Japan continues to act as a strategic reference market for global pharmaceutical pricing. Moreover, the widening of repricing rules signals long-term cost pressure for manufacturers operating in multiple international markets.
Japan’s FY26 drug price revision is increasing global pricing pressure and pushing pharmaceutical companies to reassess compliance and operational efficiency. In this context, strengthening structured quality systems becomes essential to maintain GMP stability and regulatory alignment, which is where Quality Management System plays a key supporting role.
Source: Pharmaceutical_Technology.Com